Related Experiment Video
Updated: Mar 14, 2026
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017
Circulating microRNA-137 is a potential biomarker for human glioblastoma
1Department of Neurosurgery, Zhengzhou University People's Hospital, He'nan Provincial People's Hospital, Zhengzhou, China. hang.chen2@aol.com.
Objective:
In this study, we investigated whether circulating microRNA-137 (miR-137) could be a potential biomarker for patients with glioblastoma (GBM).
Patients And Methods:
Serum samples were collected from 64 GBM patients and 64 healthy controls. The expression level of circulating miR-137 was compared by quantitative RT-PCR. Among GBM patients, circulating miR-137 was compared between patients at early stages and those at advanced stages. Also, the correlations of serum miR-137 expression with clinicopathological features and overall survival of GBM patients were statistically examined. Furthermore, whether circulating miR-137 could serve as an independent predicting biomarker GBM patients' survival was assessed.
Results:
Serum miR-137 was downregulated in GBM patients than in healthy controls. It was further downregulated in GBM patients at advanced stages than in patients at early stages. Statistical analysis demonstrated that low serum miR-137 level was strongly correlated with patients' clinical grades (p = 0.003) and KFS (p = 0.002). Low serum miR-137 was also found to be significantly correlated with, and may predict poor survival in GBM patients.
Conclusions:
Downregulated serum miR-137 may be a potential non-invasive prognostic biomarker for poor prognosis in GBM patients.
Insights
Circulating microRNA-137 (miR-137) is downregulated in glioblastoma (GBM) patients. Low serum miR-137 levels correlate with advanced disease and predict poor survival, suggesting its potential as a prognostic biomarker.
Area of Science:
- Oncology
- Molecular Biology
- Biomarker Discovery
Background:
- Glioblastoma (GBM) is an aggressive brain tumor with limited treatment options.
- Identifying reliable biomarkers for GBM prognosis is crucial for patient management.
Purpose of the Study:
- To investigate the potential of circulating microRNA-137 (miR-137) as a biomarker in GBM patients.
- To assess the correlation of miR-137 levels with clinicopathological features and survival outcomes in GBM.
Main Methods:
- Quantitative RT-PCR was used to measure serum miR-137 expression in 64 GBM patients and 64 healthy controls.
- Expression levels were compared between patient groups and correlated with clinical data and survival.
Main Results:
- Serum miR-137 was significantly downregulated in GBM patients compared to controls.
- Lower miR-137 levels were observed in advanced-stage GBM and correlated with higher clinical grades and KFS.
- Low serum miR-137 expression was associated with poor overall survival in GBM patients.
Conclusions:
- Downregulated serum miR-137 may serve as a potential non-invasive prognostic biomarker for glioblastoma.
- miR-137 warrants further investigation as a predictive tool for GBM patient outcomes.
Related Concept Videos
01:22MicroRNAs
01:22MicroRNAs